PROCEPT BioRobotics Corporation (PRCT) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $22.62: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally... Read more
Sell if holding. Engine safety override at $22.62: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 34, MACD bearish. Score 5.2/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — PROCEPT BioRobotics Corporation
Latest news
- NEWS This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday — benzinga Jun 11, 2026 neutral
- NEWS Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform, Lowers Price Target to $29 — benzinga Jun 11, 2026 negative
- NEWS PROCEPT BioRobotics Announces Two Milestones In Its WATER IV Prostate Cancer Clinical Program — benzinga May 28, 2026 positive
- NEWS Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Raises Price Target to $35 — benzinga Apr 30, 2026 positive
- NEWS 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga Apr 30, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -31.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $22.62: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 34, MACD bearish. Prior stop was $21.89. Score 5.2/10, moderate confidence.
Take-profit target: $26.29 (+16.1% upside). Prior stop was $21.89. Stop-loss: $21.89.
Quality below floor (3.2 < 4.0).
PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -29.7). TrendMatrix value score: 7.4/10. Verdict: Sell.
21 analysts cover PRCT with a consensus score of 3.9/5. Average price target: $30.
What does PROCEPT BioRobotics Corporation do?PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the...
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.